A 53-year-old man developed acute left leg pain and edema 2 weeks after lumbar interbody fusion. A computed tomography venogram demonstrated acute thrombosis extending from the deep veins of the calf all the way to and including the common iliac vein owing to external compression of common iliac vein secondary to extruded bone graft material. Endovascular intervention without the use of thrombolysis was performed using a novel percutaneous mechanical thrombectomy system (ClotTriever, Inari Medical, Irvine, Calif), allowing clot removal in single session. Clot removal and stenting were performed with resolution of symptoms and only mild swelling with prolonged standing at the 6-month follow-up. (J Vasc Surg Cases and Innovative Techniques 2019;5:302-4.) 
Acute deep vein thrombosis (DVT) continues to be a major health issue in the United States, with approximately half a million new cases annually. 1 Intervention is considered in patients with severely symptomatic proximal DVT, usually by using combined mechanical and pharmacologic methods to remove thrombus. 2, 3 Recent bleeding events or high-risk surgery can be prohibitive to the use of thrombolytic agents. In these cases, mechanical thrombectomy alone may be considered. Most devices currently used for percutaneous venous mechanical thrombectomy were initially designed for use in the arterial system and subsequently used for venous thrombosis with or without modification. With the patient's consent, we describe the use of a novel percutaneous device (ClotTriever, Inari Medical, Irvine, Calif) designed specifically for the rapid removal of large venous clot burden in proximal DVT cases.
CASE DESCRIPTION
A 53-year-old man underwent an anterior lumbar interbody fusion for isthmic spondylolisthesis at L5-S1 that was compli- CIV through the CFV with no thrombus extending into the inferior vena cava (IVC). There was also evidence of bone matrix migration from the intervertebral space that had migrated adjacent to the CIV, causing severe vein compression (Fig 1) .
Owing to the proximity of his complicated spine operation, the decision was made to proceed with mechanical thrombectomy without the use of tissue plasminogen activator. The ClotTriever System is a percutaneous device designed to facilitate the removal of significant amounts of thrombus from larger veins without the need for pharmacotherapy (Fig 2) within 6 weeks of an event. The device consists of two pieces; one is a 13F sheath equipped with a funnel at the proximal end and a large bore hemostatic valve, with attached large suction syringe, designed to facilitate clot removal in concert with the primary device, the ClotTriever catheter. The catheter incorporates a retractable coring element that, when deployed, is designed to capture thrombus from vessels up to 16 mm in diameter, which is then directed into a long collection bag that is then withdrawn through the sheath for retrieval. (Fig 4) . The patient was discharged 1 day 
DISCUSSION
The treatment for proximal DVT can range from sole medical management to use of adjunct endovascular therapies for clot debulking. The mainstay of endovascular therapies involving use of thrombolysis therapy for a period of up to 72 hours. [4] [5] [6] [7] [8] The use of thrombolysis not only increases bleeding risks for the patient, but also requires the use of intensive care unit beds, a costly expense and scarce resource in many hospitals. 9, 10 This case demonstrates the use of a novel device that allows minimally invasive clot extraction in patients with a relative or absolute contraindication to lytic therapy or those patients that would benefit from a single session treatment. The device facilitates single session treatment of acute to subacute iliofemoral and caval DVT without the need for intensive care or prolonged infusion times. Relative contraindications include the presence of an IVC filter, a venous stent, IVC clot burden, and small caliber vessels (<6 mm). Since this case was performed, improvements to the ClotTriever device have been made, allowing the reuse of devices for multiple passes through a thrombus in a case and shortening the length of the collection bag to eliminate the need to open the collection bag within the heart. Further experience will determine whether this device is cost effective in the care of patients with acute extensive DVT.
CONCLUSIONS
Symptomatic iliofemoral DVT in patients at increased risk for thrombolysis therapy can be treated quickly and efficiently using a novel percutaneous device designed specifically for single session treatment of large vein thrombosis. As this device continues to mature, further investigation will be needed to determine how it compares with other mechanical thrombectomy devices and in which patients with DVT it is most effective.
